Recently, Kanuma (sebelipase alfa) (Alexion Pharmaceuticals, Cheshire, CT) has obtained marketing authorization for the treatment of CESD in Europe and the United States with recombinant human LAL (HLAL) (13–15). Here, HLA-L is linked to cholesteryl ester storage disease.